Edwards Lifesciences Corp
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements (Unaudited)
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except par value; unaudited)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $3,110.8 | $2,938.0 |
| Short-term investments (Note 5) | 1,533.9 | 1,288.3 |
| Accounts receivable, net of allowances of $17.0 and $15.0, respectively | 784.9 | 659.6 |
| Other receivables | 152.9 | 252.5 |
| Inventories (Note 2) | 1,159.4 | 1,126.2 |
| Prepaid expenses | 147.2 | 135.0 |
| Other current assets | 358.4 | 339.3 |
| Total current assets | 7,247.5 | 6,738.9 |
| Long-term investments (Note 5) | 262.6 | 278.6 |
| Property, plant, and equipment, net | 1,858.3 | 1,811.9 |
| Operating lease right-of-use assets | 100.2 | 102.7 |
| Goodwill | 1,951.7 | 1,768.6 |
| Other intangible assets, net | 1,161.1 | 1,128.2 |
| Deferred income taxes | 929.4 | 1,138.1 |
| Other assets (Note 2) | 633.6 | 730.2 |
| Total assets | $14,144.4 | $13,697.2 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $199.7 | $227.5 |
| Accrued and other liabilities (Note 2) | 1,352.1 | 1,561.7 |
| Operating lease liabilities | 24.9 | 24.5 |
| Total current liabilities | 1,576.7 | 1,813.7 |
| Long-term debt | 598.8 | 598.3 |
| Operating lease liabilities | 80.8 | 82.6 |
| Uncertain tax positions | 580.3 | 502.7 |
| Other liabilities | 346.3 | 362.3 |
| Total liabilities | 3,182.9 | 3,359.6 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity | ||
| Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | — | — |
| Common stock, $1.00 par value, 1,050.0 shares authorized, 662.3 and 658.7 shares issued, and 575.6 and 580.7 shares outstanding, respectively | 662.3 | 658.7 |
| Additional paid-in capital | 3,057.6 | 2,768.4 |
| Retained earnings | 15,170.6 | 14,240.5 |
| Accumulated other comprehensive loss (Note 13) | (220.2) | (238.3) |
| Treasury stock, at cost, 86.7 and 78.0 shares, respectively | (7,809.2) | (7,091.7) |
| Total Edwards Lifesciences Corporation stockholders' equity | 10,861.1 | 10,337.6 |
| Noncontrolling interest | 100.4 | — |
| Total stockholders' equity | 10,961.5 | 10,337.6 |
| Total liabilities and equity | $14,144.4 | $13,697.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.